United States

Profile: Northwest Biotherapeutics Inc (NWBO.PK)

NWBO.PK on OTC Markets Group

3:59pm EDT
Change (% chg)

$0.01 (+2.58%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Northwest Biotherapeutics, Inc., incorporated on July 29, 1998, is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct.

The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer. Its DCVax platform technology involves dendritic cells, the master cells of the immune system, and is designed to reinvigorate and educate the immune system to attack cancers. The Company's DCVax technology is designed to attack the full set of biomarkers, or antigens, on a patient's cancer, rather than just a particular selected target or several targets.


The Company's product DCVax-L is designed for operable solid tumors. The DCVax-L is made with cancer antigens from tumor lysate (a protein extract from processed tumor cells) from the patient's own tumor tissue. DCVax-L incorporates a set of tumor antigens, making it difficult for tumors to find ways around it (escape variants). DCVax-L is in its 348-patient Phase III clinical trial for GBM brain cancer.


The Company's product DCVax-Direct is designed for inoperable solid tumors. The DCVax-Direct incorporates a set of tumor antigens in situ, in the patient's body rather than at the manufacturing facility. With DCVax Direct, the fresh, dendritic cells are partially matured in a way so as to be ready to pick up antigens directly from tumor tissue in the patient's body, and also communicate the information about those antigens to other agents of the immune system, such as T cells. The partially matured dendritic cells are then injected directly into the patient's tumors. DCVax-Direct is indicated for the treatment of inoperable solid tumors. There, the dendritic cells pick up the antigens- in situ rather than picking up the antigens from tumor lysate in a lab dish at the manufacturing facility, as is done with DCVax-L.

The Company competes with Juno, Kite, Bellicum, Atara, Argos, Agenus, Asterias, BMS, Merck & Co., Inc., Pfizer, Astra Zeneca, Roche Holding AG, Eisai Co. Ltd., NovoCure and MagForce Nano Technologies AG.

Company Address

Northwest Biotherapeutics Inc

4800 Montgomery Ln Ste 800
BETHESDA   MD   20814-3676
P: +1240.4979024
F: +1302.6365454

Company Web Links